Shopping Cart 0
Cart Subtotal
USD 0

Silence Therapeutics Plc (SLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a developer of therapeutics that channels gene silencing to cure disease. The company develops pipeline products such as Atu027 and Atu111. Its Atu027 is developed for the treatment of pancreatic, head and neck cancer; and Atu111 for lung indications. Silence Therapeutics also develops PF-655 for diabetic macular edema and wet age related macular degeneration; and QPI 1002 for kidney transplantation and acute kidney injury. The company has collaboration with pharmaceutical, biotechnology companies and academic research institutions. It operates in Germany and the UK. Silence Therapeutics is headquartered in London, the UK.

Silence Therapeutics Plc (SLN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Silence Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Silence Therapeutics Enters into Agreement with MiReven 10

Equity Offering 11

Silence Therapeutics Raises USD59 Million in Private Placement of Shares 11

Silence Therapeutics Announces Private Placement Of Shares For USD 16.8 Million 12

Silence Therapeutics Completes Private Placement Of Shares For USD 29 Million 13

Silence Therapeutics Completes Private Placement Of Shares For USD 8 Million 14

Silence Therapeutics Completes Rights Offering Of Shares For USD 0.39 Million 15

Silence Therapeutics Completes Private Placement Of Shares For USD 7 Million 16

Silence Therapeutics Announces Private Placement Of Shares For USD 16 Million 17

Acquisition 18

Silence Therapeutics Acquires 8.4% in Arrowhead Pharma 18

Silence Therapeutics Plc-Key Competitors 19

Silence Therapeutics Plc-Key Employees 20

Silence Therapeutics Plc-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Recent Developments 22

Financial Announcements 22

Sep 11, 2018: Silence Therapeutics: Interim results for the six months ended 30 June 2018 22

Mar 06, 2018: Silence Therapeutics: Preliminary results for the year ended 31 December 2017 27

Sep 06, 2017: Silence Therapeutics: Interim results for the six months ended 30 June 2017 31

Mar 28, 2017: Silence Therapeutics: Preliminary results for the year to 31 December 2016 32

Corporate Communications 34

Aug 20, 2018: Silence Therapeutics announces board change 34

Jul 17, 2018: Silence Therapeutics Names David Horn Solomon as chief executive officer 35

Jun 21, 2018: Silence Therapeutics Announces Board Changes 37

Jun 04, 2018: Silence Therapeutics Announces Senior Management Change 38

Oct 16, 2017: Appointment of Dr. Annalisa Jenkins, MBBS, FRCP as Non-Executive Chair 39

Jul 14, 2017: Silence CEO, Ali Mortazavi, appointed Chairman of Ultromics 40

Legal and Regulatory 41

Nov 20, 2017: Silence Therapeutics: Update on litigation matters 41

Nov 03, 2017: Silence Therapeutics: Update on litigation matters 42

Oct 17, 2017: Silence Therapeutics: Serving of claim in the UK High Court 43

Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 44

Other Significant Developments 45

Jan 08, 2018: Silence Therapeutics: Post year end business update 45

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Silence Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Silence Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 8

Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Silence Therapeutics Enters into Agreement with MiReven 10

Silence Therapeutics Raises USD59 Million in Private Placement of Shares 11

Silence Therapeutics Announces Private Placement Of Shares For USD 16.8 Million 12

Silence Therapeutics Completes Private Placement Of Shares For USD 29 Million 13

Silence Therapeutics Completes Private Placement Of Shares For USD 8 Million 14

Silence Therapeutics Completes Rights Offering Of Shares For USD 0.39 Million 15

Silence Therapeutics Completes Private Placement Of Shares For USD 7 Million 16

Silence Therapeutics Announces Private Placement Of Shares For USD 16 Million 17

Silence Therapeutics Acquires 8.4% in Arrowhead Pharma 18

Silence Therapeutics Plc, Key Competitors 19

Silence Therapeutics Plc, Key Employees 20

Silence Therapeutics Plc, Other Locations 21

Silence Therapeutics Plc, Subsidiaries 21

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Silence Therapeutics Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.